Clinical Trials Logo
  1. Home
  2. Silicosis
  3. NCT01977131
  4. Details
NCT01977131 Clinical Trial

Safety Study of Autologous Bone Marrow Stromal Cells With Modification by Hepatocyte Growth Factor to Treat Silicosis

Silicosis Clinical Trial

Official title:
Phase 1 Study of Autologous Bone Marrow Stromal Cells With Modification by Hepatocyte Growth Factor to Treat Silicosis

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01977131
Other study ID # 2010B031600019
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received October 30, 2013
Last updated November 20, 2013
Start date June 2010
Est. completion date September 2013

Study information
Verified date November 2013
Source Guangzhou Municipal Twelfth People's Hospital
Contact n/a
Is FDA regulated No
Health authority China: Ministry of Science and Technology
Study type Interventional

Clinical Trial Summary

The aim of this study was to analyze the safety, pulmonary function, and imaging changes of patients with silicosis treated with autologous bone marrow stromal cells with modification by hepatocyte growth factor.

Recruitment information / eligibility
Status Completed
Enrollment 10
Est. completion date September 2013
Est. primary completion date June 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- age between 18-50, chronic and accelerated silicosis, characterized with a fibrotic increase in the last two years, FEV1 <60% and > 40%, FVC > 60% and SaO2 >90%

Exclusion Criteria:

- smoking, active tuberculosis or other infections, cancer, auto-immune disorders, hematological, hepatic or cardiac diseases, and pregnancy

Study Design

Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Other:
• Cells

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Wei Yu

Outcome
Type Measure Description Time frame Safety issue
Primary Absence of lung deficits during the procedure and/or in the 6 months follow-up 6 months Yes
Secondary Improvement of pulmonary deficits 1 year Yes
See also
  Status Clinical Trial Phase
Not yet recruiting NCT01329003 - DNA-damage Pathways in Workers Exposed to Silica (Caesar Stone) N/A
Not yet recruiting NCT01338064 - Oxidative Stress Biomarkers to Monitor and Early Detect Health Impairment in Workers Exposed to Silica (Caesar Stone) N/A
Recruiting NCT04161014 - The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial Phase 2
Recruiting NCT05118256 - Pirfenidone for the Reduction of Metabolic, Inflammatory and Fibrogenic Activity in Complicated Silicosis Phase 2
Completed NCT02430259 - Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention Phase 3
Not yet recruiting NCT06011785 - Using Silica 12CH to Mitigate the Effects and Symptoms of Silicosis in Brazil Early Phase 1
Not yet recruiting NCT05402176 - The SHIELD Whole Lung Lavage Study
Completed NCT02794701 - Comprehensive Risk Assessment of People With Silicosis: A Population-based Study
Completed NCT00005280 - Specialized Center of Research in Occupational and Immunologic Lung Disease N/A
Recruiting NCT05538299 - Silicosis Treatment, Action, Screening and Surveillance in Rwanda Trials
Completed NCT01725971 - Oscillation Mechanics of the Respiratory System in Never-smoking Patients With Silicosis N/A
Recruiting NCT06090370 - Reducing Silica Exposure Among Brick Kiln Workers in Nepal N/A
Completed NCT04205708 - Screening Strategy for Early Diagnosis of Silicosis in At-Risk Populations in Oklahoma
Recruiting NCT05546944 - The SHIELD Study-silicosis